News Breaks |
|
|
| January 6, 2013 |
| 11:42 EDT |  | AMAG | AMAG sees FY13 revenue $73M- $77M, consensus $79.12M
AMAG sees Feraheme U.S. net product revenues of between $63M-$67M, driven by a combination of price and double-digit volume growth; Royalties and product sales related to ex-U.S. sales of Feraheme/Rienso and recognition of milestones of approximately $10M. |
|
|
News For AMAG From The Last 14 Days Check below for free stories on AMAG the last two weeks. |
|
|
| May 22, 2013 |
| 08:59 EDT |  | AMAG | On The Fly: Pre-market Movers
 Subscribe for More Information |
|
| May 21, 2013 |
| 18:56 EDT | | AMAG | On The Fly: After Hours Movers
Subscribe for More Information |
|
| 17:34 EDT | | AMAG | AMAG says Takeda recalling one batch of Rienso from Swiss market
Subscribe for More Information |
|
| 08:47 EDT | | AMAG | AMAG Pharmaceuticals Ferumoxytol treatment significant hemoglobin increases
AMAG Pharmaceuticals announced that a new sub-group analysis from IDA-301, a phase III, randomized, placebo-controlled clinical trial, will be presented today at the Digestive Disease Week 2013 meeting in Orlando, Florida. In the full IDA-301 study, 608 adult patients with iron deficiency anemia who had failed or could not tolerate oral iron were treated with ferumoxytol and 200 received placebo. The data from this study showed a direct correlation between a rise in hemoglobin levels and improvements in patients' self-reported measures of fatigue. GI patients with iron deficiency anemia who have not responded well to oral iron supplementation have a need for additional treatment options. The analysis from this study supports the potential of ferumoxytol as a new treatment option for patients with IDA from GI disease who have previously had an unsatisfactory response to oral iron therapy |
|
| May 15, 2013 |
| 09:53 EDT |  | AMAG | AMAG Pharmaceuticals management to meet with Leerink
Subscribe for More Information |
|
|
|
|
|
